Barrow, Hanley, Mewhinney & Strauss
ZBH icon

Barrow, Hanley, Mewhinney & Strauss’s Zimmer Biomet ZBH Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-388
Closed -$45K – 445
2017
Q4 		$45K Buy
388
+22
+6% +$2.49K ﹤0.01% 353
2017
Q3 		$42K Buy
+366
New +$42.2K ﹤0.01% 366

Other funds holding ZBH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LP
Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's ZBH Position: Q1 2018 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Zimmer Biomet (ZBH) in Q1 2018, closing a stake of 388 shares — an estimated $45K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in ZBH in Q3 2017 and held it in 2 quarters. The position peaked at $45K in Q4 2017. 875 funds tracked by Wall St. Rank hold ZBH as of Q1 2018.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Zimmer Biomet position as of Q1 2018 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 388 Zimmer Biomet shares in Q1 2018, an estimated $45K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Zimmer Biomet in Q3 2017 and held it in 2 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Zimmer Biomet position peaked at $45K in Q4 2017.
  • 875 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2018.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2018, filed 14 May 2018.